Could SHP2 inhibition overcome osimertinib resistance in NSCLC?

Recent preclinical research from the University of Texas MD Anderson Cancer Center (TX, USA) and Navire Pharma, Inc (San Francisco, CA, USA) has shown IACS-13909, a novel SHP2 inhibitor, can provide tumor regression in NSCLC that has developed resistance to osimertinib. Based on the data, Navire Pharma plan to begin clinical studies before the end of 2020. The data, published today in Cancer Research, represents the first disclosure of IACS-13909, a potent and selective Src homology 2 domain-containing phosphatase. The molecule was initially developed through collaboration with Navire at MD Anderson’s Therapeutic Discovery research division. Osimertinib has received a flurry...